I am starting to now believe - rather than hope, that all 4 of the current phase 2 trials will be successful.
Similar ailments treated by the same drug.
Efficacy is the only real variant.
And then phase 3 - with this science? With this management team - I believe they will be successul too (albeit with the fact that Neuren themselves have not as yet got a drug past phase 3).
They must have learnt something with Trofinetide regarding that! And they have plenty of cash to hire/contract the right people to do the job.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.66 |
Change
-0.040(0.24%) |
Mkt cap ! $2.098B | |||
| Open | High | Low | Value | Volume |
| $16.68 | $16.86 | $16.51 | $2.872M | 172.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 396 | $16.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.66 | 158 | 10 |
View Market Depth
| Last trade - 14.48pm 30/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |